Nikolaos-Iasonas Kouris

Dr. Nikolaos-Iasonas Kouris

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2021 in Immunotherapy
Verified
Journal Article
Closed access
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
STSergios Tsakatikas
Sergios Tsakatikas
NKNikolaos-Iasonas Kouris
Nikolaos-Iasonas Kouris
GPGeorge Papaxoinis
George Papaxoinis
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS
Gastric cancer, the fifth most frequent cancer and the fourth leading cause of cancer deaths, accounts for a devastating death rate worldwide. Since the majority of patients with gastric cancer are...

1 September 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
Christo KOLEChristo KOLE
Christo KOLE
Nikolaos CharalampakisNikolaos Charalampakis
Nikolaos Charalampakis
MVMichail Vailas
Michail Vailas
Maria ToliaMaria Tolia
Maria Tolia
MSMaria Sotiropoulou
Maria Sotiropoulou
DIMITRIOS SCHIZASDIMITRIOS SCHIZAS
DIMITRIOS SCHIZAS

Verified
Journal Article
Open access
PDF file
NKNikolaos-Iasonas Kouris
Nikolaos-Iasonas Kouris
Charalampos FilippatosCharalampos Filippatos
Charalampos Filippatos
KLKonstantinos Lallas
Konstantinos Lallas
SSSofia Spyropoulou
Sofia Spyropoulou
PMPanagiotis Malandrakis
Panagiotis Malandrakis
Ioannis Ntanasis-StathopoulosIoannis Ntanasis-Stathopoulos
Ioannis Ntanasis-Stathopoulos
Background: Programmed death-1 (PD-1) inhibitors have significantly improved survival outcomes in melanoma; however, questions persist regarding comparative efficacy across regimens and the predictive value of PD-L1 expression as a biomarker. We therefore performed a meta-analysis evaluating outcomes according to PD-L1 expression status using the most recent follow-up data from each study. Methods: A systematic search was conducted in PubMed, Cochrane and ClinicalTrials.gov from 1 January 2010 to 1 April 2025 for phase II and III randomized clinical trials (RCTs) investigating PD-1 inhibitors as monotherapy or combined with other immune checkpoint inhibitors (ICIs) or targeted therapy in the adjuvant/metastatic setting. Pooled estimates were calculated with random-effects models, and risk of bias was assessed using the Cochrane RoB 2 tool. The present meta-analysis was performed following PRISMA guidelines and was registered in PROSPERO (ID: CRD420251090090). Results: Fifteen RCTs including 9979 patients were included. In the overall analysis, PD-1 inhibitors were associated with significantly improved overall survival (OS, HR = 0.75, 95% CI: 0.66–0.86) compared with control treatments. In the unresectable or metastatic setting, progression-free survival (PFS) was also significantly improved (HR = 0.61, 95% CI: 0.49–0.76). Survival benefits were observed in both PD-L1-positive and PD-L1-negative tumors, with improved PFS in PD-L1-positive (HR = 0.63, 95% CI: 0.48–0.83) and PD-L1-negative patients (HR = 0.58, 95% CI: 0.44–0.77), as well as improved OS in PD-L1-positive (HR = 0.69, 95% CI: 0.59–0.80) and PD-L1-negative patients (HR = 0.79, 95% CI: 0.67–0.93), without evidence of effect modification by PD-L1 expression. PD-1 inhibitor-based regimens were not associated with a statistically significant increase in grade 3–4 treatment-related adverse events (RR = 1.13, 95% CI: 0.71–1.79); however, heterogeneity was substantial (I2 = 96.0%). Conclusions: PD-1 inhibitor-based therapies significantly improve survival outcomes in advanced melanoma across PD-L1 subgroups. No clear evidence of differential treatment benefit according to PD-L1 expression was observed, suggesting limited utility as a standalone predictive biomarker. Further studies integrating molecular and immune profiling are warranted to optimize individualized treatment selection.